Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 8/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24810574 | 0.94 | ALDH1A1 (0.41) | POLBNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL24809418 | 0.91 | CNR2 (0.41) | HPGDSNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL24810582 | 0.90 | CNR1 (0.39) | — | |
| SCHEMBL24809758 | 0.83 | MAPK8 (0.36) | ALDH1A1MAPT | |
| SCHEMBL24809411 | 0.82 | CHRM4 (0.40) | CHRM4POLBNPC1RAB9AALDH1A1 | |
| SCHEMBL24810688 | 0.81 | PDCD1LG2 (0.36) | HPGDSCHRM4POLBNPC1RAB9A | |
| SCHEMBL24809766 | 0.80 | BCHE (0.34) | HPGDSCHRM4POLBNPC1RAB9A | |
| SCHEMBL24809406 | 0.78 | NAMPT (0.36) | KMT2A | |
| SCHEMBL24809790 | 0.77 | MAPT (0.38) | CHRM4POLBNPC1RAB9AALDH1A1 | |
| SCHEMBL24811087 | 0.77 | NAMPT (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411388-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-29 | — | — | US | disclosed |
| US-20220411388-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-29 | — | — | US | disclosed |
| EP-4031531-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| CN-114787135-A | Substituted imidazole carboxamides and their use in the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-07-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411388-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, CLN6 | HPGDS 1790/4885CHRM4 3932/4885POLB 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.